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Background. Though Helicobacter pylori (HP) infections have progressively declined throughout most of the industrialized
countries, a gradual increase in failure of HP eradication treatments is observed. Aim. To critically review evidence on the eﬃcacy
of the therapeutic availabilities for HP eradication, as yet. Methods. A selection of Clinical Trials, Systematic Reviews and Meta-
analyses within the time period 2010–2012, was performed through a Medline search. Previous references were included when
basically supporting the first selection. Results. An increasing rise in HP resistance rates for antimicrobial agents is currently
observed. Further causes of HP treatment failure include polymorphisms of the CYP 2C19, an increased body mass index
(BMI), smoking, poor compliance and re-infections. Alternative recent approaches to standard triple therapy have been attempted
to increase the eradication rate, including bismuth-containing quadruple therapy, non-bismuth containing quadruple therapy,
sequential therapy and levofloxacin-containing regimens. Conclusions. The main current aims should be the maintenance of a high
eradication rate (>85%) of HP and the prevention of any increase in antimicrobial resistance. In the next future, the perspective
of a tailored therapy could optimize eradication regimens within the diﬀerent countries.
1. Introduction
Helicobacter pylori (HP) is an ubiquitous gram-negative
bacterium. Its specific microbiological features allow its
survival in the stomach and the colonisation of the antrum.
HP expresses high levels of urease enzyme, producing NH3
and CO2 from the urea being present in the gastric juice
[1]. This mechanism called acid acclimation regulates the
cytoplasmic pH of the bacterium and guarantees the mainte-
nance of a periplasmic pH near neutrality, despite the acidic
environment [2]. Once HP has colonised the stomach, an
immune response begins; as a result, normal acid secretion
and gastric architecture are modified. Consequences are
gastritis, peptic ulcer disease, functional dyspepsia, and
cancer. HP was first identified in 1982 and by 1989 had been
associated with gastric inflammation and ulcers in adults
and children [3]. During the 1990s evidence emerged of its
etiologic role in stomach cancers in adults. HP was classified
in 1994 among the group I carcinogens by the International
Agency for Research on Cancer [4]. There are also a
lot of associations between HP and other extra intestinal
diseases such as cardiovascular diseases, diabetes mellitus,
lung diseases, hematologic diseases, neurological diseases,
and glaucoma. Nevertheless, more studies are necessary to
delineate the cause-eﬀect relationship for any of these issues
[5]. Helicobacter pylori infects approximately 50% of the
adult population [1, 6]: only 20% of HP-infected people are
symptomatic whereas 80% of them are symptom-free.
2. Aim and Methods
This paper is conceived to critically review evidence on the
eﬃcacy of the therapeutic availabilities for HP eradication,
available as yet. A Medline search was performed indicating
as keywords “Helicobacter,” “Eradication Regimens,” “Erad-
ication Rate,” “Epidemiology,” “Drug Resistance.” A selec-
tion of relevant English-language clinical trials, systematic
reviews, and meta-analyses within the time period 2010–
2012 was performed. Previous references were included
when basically supporting the first selection. PubMed,
Cochrane Library, Trip Database, and Ovid Medicine were
used as referral databases.
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Jadad Scale (score 0 to 5) was used as a predetermined
strategy of inclusion for clinical trials.
3. Epidemiology of H. pylori Infection
Over recent decades, HP infections have progressively
declined throughoutmost of the industrialized countries. HP
still represents, by the way, a clinical issue among those
people who were infected as children at a time when HP
was endemic or among immigrants coming from endemic
countries [14, 15]. Many diﬀerent factors play a role in the
development of HP infection, including geography, ethnicity,
age, and socioeconomic elements [15]. The progressive
decline in infection rates has been secondary to the improve-
ments in sanitation as well as to the use of combination of
anti-HP regimens over the past decades.
At the same time, a gradual increase in failure of HP
eradication treatments is found [16] and the task of treating
HP has now become increasingly challenging: a fall in the
eradication success with standard triple therapy from over
90% in the 1990s to <60% is observed nowadays [17].
The main reason for eradication failures is antimicrobial
resistance, in particular clarithromycin (CAM) resistance
relates to a reduction in the success of standard triple
therapies by 35–60% [18].
4. Helicobacter pylori : Drug Resistance
Since resistance rates for antimicrobial agents rise with their
indiscriminate use, clarithromycin (CAM) resistance may be
due to the widespread use of this agent for upper respiratory
tract infections [19, 20]. De Francesco et al. showed [21]
that HP antibiotic resistance rates all over the world are
17.2% for CAM, 26.7% for metronidazole (MNZ), 11.2%
for amoxicillin, and 16.2% for levofloxacin. It is known
that bacteria can develop eﬄux channels for CAM, which
rapidly transfer the drug out of the bacterial cell, preventing
the binding of the antibiotic to the ribosome [22]. It has
been speculated that the disruption of the cell wall caused
by amoxicillin prevents the development of eﬄux channels
by damaging the wall of the bacterium, thus improving the
eﬃcacy of CAM in a second phase of treatment [23]. It has,
however, to be taken into consideration that the improved
eﬀect with sequential and concomitant therapies compared
with standard therapy may also be due to the larger number
of antibiotics than to the sequential administration itself
[24]. Since one meta-analysis reported an almost 60%
decline in eradication rates with standard triple therapy if
CAM resistance was present [25], the use of standard triple
therapy has been recommended only in those areas where
CAM resistance is lower than 15–20%. As a general rule,
clinicians should prescribe therapeutic regimens that have
a ≥90% eﬃcacy [26]. There are several reasons causing
treatment failure, the antimicrobial resistance being the most
important; other lower causes are polymorphisms of the
CYP 2C19, an increased body mass index (BMI), smoking,
poor compliance, and reinfections [8, 27–29]. Since all
the diﬀerent HP therapies are long and complicated, a
poor compliance is often found as the real reason of a
treatment failure, particularly in the developed countries.
New strategies to improve compliance should therefore be
applied [30].
The prevalence of antimicrobial resistance might be sig-
nificantly diﬀerent between countries, which will greatly
aﬀect eradication rates [1, 31]. For example, a significant
increasing rate of resistance to CAM and MNZ in some
parts of Asia including Japan [32] determines a reduced
eﬃcacy of PPI-based triple therapy. Cases of Nitroimidazole
resistance as well as dual resistance (to both CAM andMNZ)
are described [33]. For these latter patients, concomitant
therapy may be more suitable than sequential therapy. The
increase in MNZ resistance appears, however, less important
with respect to CAM, as a dose increase and a longer
treatment period consent to avoid HP infection. Given the
described geographical variability, the development of better
treatments for HP infection should take into consideration
the distribution of antibiotic resistance among aﬀected
populations in diﬀerent geographical areas; however, these
data are still lacking outside the USA. A recent meta-analysis
of five randomized controlled trials totalling 701 patients
[34] showed that culture-guided triple therapy is superior to
standard triple therapy referring to a higher eradication rate
from intention-to-treat analyses (CI 0.77–0.9, P < 0.00001)
and a lower overall cost. Antimicrobial susceptibility testing
is therefore recommended before first-line treatment for HP
infection. Another important factor is polymorphism of the
CYP2C19 isoenzyme [35, 36] that is responsible for the
biotransformation of several PPIs: significant diﬀerences in
eradication rates have been observed between homozygous
and heterozygous extensive metabolizers and poor metabo-
lizers of PPIs (omeprazole being the most aﬀected, followed
by lansoprazole). As a consequence, the use of higher doses
may be required. Orientals, for instance, are lowmetabolizers
than Caucasians. The influence of age on the eﬃcacy of
concomitant treatment is unclear; the only study that has
evaluated concomitant therapy in children showed favorable
results (94% of eradications in 33 children) [37]. Gender
was not found to be a significantly predictive factor for
success or failure of HP eradication in patients treated with
concomitant therapy [38]. The main current eﬀort should
be to maintain the eradication rate of HP above 85% and to
prevent any increase in antimicrobial resistance in the general
population.
The possibility of a tailored therapy will be a chance in
the next future to optimize the most eﬀective eradication
regimen within the various geographical areas; for this
proposal, the determination of HP genotype from gastric
tissue samples or stools as well as the determination of
CYP2C19 polymorphism is required [39].
5. Therapeutic Approaches Attempted
for Eradication of H. pylori
The most widely recommended treatment in international
guidelines for the eradication of HP is the Standard Triple
Therapy based on a proton-pump-inhibitor (PPI) to which
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Table 1: Summary of the main current first- and second-line treatment regimens available for HP eradication.
First-line treatment regimens
Triple standard therapy PPI + CAM + AMPC and/or MNZ
Eradication of HP infection from 90% to 70–80%
Steadily decline in treatment eﬃcacy in USA [7]
Sequential therapy
PPI + AMPC for 5 days, then PPI + CAM
+ MNZ for other 5 days
Eradication rates of 90%–94% [8, 9]
Concomitant therapy
PPI + CAM + AMPC + MNZ for 7–10
days
Eradication rate of 90%. More simple regimen, good
alternative to standard triple therapy [10]
Bismuth-based quadruple
therapy
PPI + Bismuth + Tetracycline + MNZ for
10–14 days
Important role in countries with high CAM resistance
rate; in a recent study patients took PPI and a
three-in-one capsule containing bismuth subcitrate
potassium, MNZ and Tetracycline with eradication
rates of 80% versus 55% in the standard therapy group
[11]
Second-line treatment regimens
Levofloxacin-based triple therapy PPI, levofloxacin, and AMPC
Good alternative for patients who failed with standard
treatment. A recent meta-analysis highlighted that
levofloxacin-based triple therapy has lower incidence in
side eﬀects than the bismuth-based quadruple therapy,
as well as a better eradication rate (87% versus 68%)
[12]
Rifabutin-containing rescue
therapy
Well tolerated, good alternative for patients who failed
with a first-line therapy [13]
AMPC: amoxicillin, MNZ: metronidazole, CAM: clarithromycin, and PPI: proton pump inhibitor.
two antibiotics (CAM plus amoxicillin (AMPC or MNZ)
are associated for 7 days [37–41]. With few exceptions, the
standard triple therapy now provides unacceptably low treat-
ment success (i.e., 80% or less) [42]: two recent double-blind
multicentre studies have evidenced low eradication rates with
standard therapy (77%)[43, 44] and two meta-analyses on
more than 53.000 patients have confirmed this data [45, 46].
As a consequence, new alternative recent approaches have
recently been attempted to increase the intention-to-treat
(ITT) eradication rate, possibly over 85% (Table 1) [47]. For
many years, a recommended alternative approach (Maas-
tricht III Consensus and Guidelines of American College of
Gastroenterology) has been the addition of PPIs to the old
regimen comprising a bismuth salt, tetracycline, and MNZ
[48]. A meta-analysis on triple versus bismuth-containing
quadruple Therapy for HP infection demonstrated that 80%
of patients who received quadruple therapy and 79% of
patients who received triple therapy achieved eradication by
ITT analysis, indicating a similar eﬀectiveness for the two
regimens, even though bismuth-based quadruple therapy is
known to be useful after failure of PPI-based triple therapies
(average eradication rate of 76% for quadruple therapy when
used as second-line therapy) [49, 50].
An eﬃcacy of ranitidine bismuth-based triple therapies
has also been demonstrated as retreatments [51]. Non-
bismuth quadruple therapy (PPI-CAM-AMPC-nitroim-
idazole) also represents a safe alternative to triple therapy and
should be taken into consideration when the eﬃcacy of triple
therapy results in being unacceptably low [33]. A review
article by Gisbert et al. [52] critically evaluated the evidence
existing on the role of non-bismuth quadruple therapy
(PPI-clarithromycin-amoxicillin-nitroimidazole) [53–55] in
the treatment of HP infection. This regimen appears to be
eﬀective, safe, and suited for use in settings where the eﬃcacy
of triple therapy is unacceptably low.
Because of the scarce compliance to these regimens as
well as the increased resistance to both CAM and MNZ,
the “sequential therapy” was introduced as a promising new
treatment comprising 5 days of amoxicillin with a PPI,
followed by 5 days of the same PPI but with a nitroimidazole
(tinidazole, MNZ) together with CAM. The sequential ther-
apy was largely experimented in Italy where an increase in the
eradication rate by at least 10%was observed, compared with
standard regimens, independently on clarithromycin resis-
tance [56, 57]. This regimen has been demonstrated more
eﬀective than standard triple therapy by several clinical trials
and meta-analyses [58, 59]. By the way, sequential therapy
has not been subjected to any clinical trial in the United
States, yet. A recent trial in South America, demonstrated the
standard 14-day triple therapy to be more eﬃcacious than
the 10-day sequential four-drug regimen [60]. A study by
Hsu et al. on a cohort of patients in Taiwan, compared an
extended 14-day therapy to the 10-day sequential therapy,
without attesting any improvement [61]. A study by Miehlke
et al. showed that a high-dose PPI dual therapy with AMPC
was eﬀective as a salvage treatment for eradication of H.
pylori resistant to both CAM and MNZ, with an ITT of 76%
[62]. A study by Attumi and Graham evaluated the eﬃcacy
of a prolonged dual therapy (AMPC and omeprazole for
6 weeks) without attesting any improvement in treatment
outcome (ITT of 63%)[63], thus suggesting that extending
the duration of a dual therapy to more than 14 days is not
eﬀective for achieving an improved treatment outcome [47].
What finally emerges from this study is that higher doses
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and more eﬀective agents represent a stronger approach for
HP eradication than the simply longer duration [47]. The
nonbismuth quadruple therapy and the sequential regimens
resulted in being similar in terms of eﬃcacy and safety.
Several randomised controlled trials and meta-analyses have
demonstrated that non-bismuth quadruple therapy is more
eﬀective and equally well tolerated as standard triple therapy.
A meta-analysis of 15 studies showed a mean cure rate of
90% for non-bismuth quadruple therapy. CAM resistance
may reduce the eﬃcacy of non-bismuth quadruple therapy,
although the eradication rate remains much higher than
in standard triple therapy. Many studies have included
Levofloxacin and shown good eradication rates, indicating
a levofloxacin-based triple therapy as another option for
patients with persistent infections [64].
In a recent trial by Basu et al. [65] a new regimen with
high eradication rate was proposed: a novel drug combina-
tion was tested within a clinical trial and compared with
a standard triple therapy (amoxicillin, CAM, and lansopra-
zole). This new regimen was called LOAD as it comprised
three antibiotics (levofloxacin, doxycycline, and nitazox-
anide, a prodrug with antiparasitic properties) together with
omeprazole; its eﬃcacy was supported by an eradication rate
of 90% compared with 73% with the triple therapy. This
relatively expensive novel drug combination would represent
an absolute increase of 17% in the eradication rate (with
a needed to treat number of 5.88 to achieve one more
successful eradication). A concrete advantage of this regimen
is the exclusion of any penicillin-based antibiotic, so that
in those patients a real or perceived allergy to penicillin
can be treated as well [7]. To be noticed as a limitation
in the application of this regimen is the fluoroquinolone
levofloxacin included in the treatment, which appears to
rapidly generate resistance, with a peculiar increase recently
demonstrated among Asian populations [9]. The elevated
cost of nitazoxanide is also a socioeconomically issue to
be take into consideration as regards the compliance to
this new regimen proposed [7]. In Asia, the currently
recommended first-line therapy for H. pylori infection is
a PPI, AMPC, and CAM for 7 days [49]. According to
the Maastricht III consensus, in naı¨ve HP-infected patients,
triple therapy using a PPI with CAM and AMPC or MNZ
remains the recommended first-choice treatment [10]. Some
authors have demonstrated the importance of H. pylori CagA
status for the eﬃcacy of antibiotic treatment considering an
infection with cytotoxic strains as a good predictive marker
of successful therapy [11–13, 66]. A useful role for some
probiotics including S. boulardii and L. reuteri as an adjunct
to HP eradication treatment has recently been established
[67, 68].
6. Managing HP Infection in Children: The 2011
ESPGHAN and NASPGHAN Guidelines
In 2011 the European and North American Societies
of Pediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN and NASPGHAN) emitted evidence-based
guidelines for managing HP in children [69]. These guide-
lines suggest to assess not only the presence of the HP
infection but also all the other possible underlying causes
of the specific clinical features. They recommend to test
children having first-degree relatives with gastric cancer as
well as children showing refractory iron-deficiency anemia
with previous negative tests for other causes. Instead, screen-
ing for HP is not recommended in children with suspect
of functional abdominal pain. HP positive peptic ulcer
disease (PUD) is recommended for treatment. However,
for children with HP infection without PUD, treatment
should be considered by the clinician evaluating the potential
advantages and the risk factors of a developed chronic
infection with bad consequences. In children, the first-line
recommended therapies are
(1) standard triple therapy with PPI (1-2mg/kg/day),
AMPC (50mg/kg/day), CAM (20mg/kg/day), or
MNZ (20mg/kg/day);
(2) bismuth-based quadruple therapy: bismuth subsal-
icylate (8mg/kg/day), AMPC (50mg/kg/day), and
MNZ (20mg/kg/day);
(3) sequential therapy: PPI (1-2mg/kg/day) AMPC
(50mg/kg/day) for 5 days, then PPI (1-2mg/kg/day),
CAM (20mg/kg/day), and MNZ (20mg/kg/day) for
5 days.
As for adults, an antibiotic susceptibility test should be
performed whenever a high resistance rate (>20%) in the
area is known. Once treatment is completed a non invasive
test should be done to ensure eradication [69].
7. H. pylori Infection and Diseases of
the Upper Gastrointestinal Tract
Over the past two decades, HP has represented a pivotal
role in nonmalignant diseases of the upper gastrointestinal
tract, as peptic ulcer disease (PUD), functional dyspepsia
(FD), and gastroesophageal reflux disease (GERD) [70].
Irrespective of etiology, both incidence and prevalence of
uncomplicated PUD have dramatically decreased in the
developed countries in the last decades. By the way, rates
of both ulcer complications and mortality still remain
high nowadays. The prevalence of HP-associated ulcers is
decreasing, whereas a role of nonsteroidal anti-inflammatory
drugs (NSAID) is becoming predominant. In fact, in western
countries a decline of HP prevalence is described as well
as an increasing use of NSAIDs and aspirin, the latter
mainly prescribed for cardiovascular protection [70]. As HP-
related PUD is the cause of symptoms in only a minority
of patients with dyspepsia, recommendations on HP testing
and subsequent eradication in all patients with dyspeptic
symptoms vary greatly [71].
As regards FD (as defined by Rome III criteria) a
possible role of HP still remains uncertain [69]. The
pathophysiology of FD is actually multifactorial. Several
randomized controlled trials performed in western countries
and in Asia have given opposite results about the role of HP
infection in causing FD, with no evidence for the former
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countries whereas a success of eradication has been obtained
in some east Asian populations [70]. As HP may reduce
gastric acid secretion, its colonisation has been reported
to be inversely associated with the development of GERD
[72]. HP infection would be protective towards gastroe-
sophageal disease (GERD). By the way, HP is associated
with esophageal squamous cell carcinoma, and long-term
PPI treatments in patients with persistent HP infection may
cause gastric atrophy, which is a precancerous lesion [72,
73]. It is reported that the widespread use of eradication
therapy with a falling prevalence of HP infection has been
paralleled with an increase in the occurrence of GERD
[74]. By the way, other studies evaluating the same relation
actually produced inconsistent results [75]. A systematic
review by Qian et al. [76] was aimed to evaluate whether
the eradication of HP would worsen or improve GERD,
both from the clinical (heartburn, acid regurgitation) and
endoscopical (erosive esophagitis) point of view. The 11
articles included in this met-analysis showed no significant
diﬀerence between patients with HP eradicated and those
with persistent infection. The authors therefore concluded
that HP eradication does not worsen the clinical outcomes
of GERD. Gastric cancer remains a major cause of cancer
death worldwide [77]. Its pathogenesis is multifactorial
and involves bacterial, host, and environmental factors that
interplay in the histological progression to neoplasia. HP has
been recognized as a major factor in the early stages of cancer
development, so its screening and eradication are mandatory
for cancer prevention. Population-based screening represents
the current best option for the primary prevention of gastric
cancer, the incidence of which largely depends on diﬀerences
in HP CagA status and dietary factors [13, 66, 78]. To
predict the risk of gastric cancer development and diagnose
atrophic gastritis, new serologic testing for a combination
of pepsinogen I and II and gastrin and HP antibodies has
yielded satisfactory results over the last decades. Also old
age, alcohol, and smoking habits are risk factors for gastric
cancer. A prevention of gastric cancer can be obtained by
eradication of HP, the success of which depends on the degree
of preneoplastic changes (gastric atrophy and intestinal
metaplasia) at the time of eradication.
Virulence determinants of HP may be connected to
gastric carcinogenesis; the use of genomewide germline
analyses might oﬀer the chance to identify high-risk groups
of gastric cancer [79].
8. Conclusions
Many diﬀerent factors play a role in the development of HP
infection, including geography, ethnicity, age, and socioeco-
nomic elements. The eﬃcacy of various available treatment
strategies varies significantly within diﬀerent regions. A
progressive decline in infection rates has been secondary
to the improvements in sanitation as well as to the use of
combination anti-HP regimens over the past decades. The
gradual increase in failure of HP eradication treatments is
mainly secondary to antimicrobial resistance, in particular to
clarithromycin.
Quadruple therapy (PPI + CAM + AMPC and/or MNZ
± Bismuth) and sequential therapy (PPI + AMPC for 5 days,
then PPI + CAM + MNZ for other 5 days) are eﬃcacious
alternatives to standard triple therapy for both adults and
children. The main current eﬀort should be to maintain the
eradication rate of HP above 85% and to prevent any increase
in antimicrobial resistance in the general population. The
possibility of a tailored therapy will be a chance in the next
future to optimize the most eﬀective eradication regimen
within the various geographical areas.
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